AIPLA Rapid Response Webinar: Amgen v Sanofi: Settling the Law on Enablement or Raising More Questions?
June 13, 2023 12:30 PM to 2:00 PM
Contact
Email: cle@aipla.org
Credits
No CLE
Registration
Fee: Free, Members Only
Registration closes June 13, 2023 at 1:00 PM
Register Now
Please join AIPLA for a Rapid Response webinar on the U.S. Supreme Court’s decision in Amgen v Sanofi: Settling the Law on Enablement or Raising More Questions?
Speakers:
Christopher Holman: UNIVERSITY OF MISSOURI-KANSAS CITY
Kevin Noonan: McDonnell Boehnen Hulbert & Berghoff LLP
Gina Shishima: Norton Rose Fulbright
Andrew Brabury: Specifica
Moderator: Carla Mouta-Bellum, Arrigo, Lee, Guttman & Mouta-Bellum, LLP
This is a free, members only webinar. No CLE
Add to:
News
-
AIPLA Comments to the Copyright Office on Alternative Fee Structures for Registration
July 6, 2026
Alexandria, VA. June 24, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the U.S. Copyright Office's Notice of Inquiry regarding alternative copyright registration fee structures. -
AIPLA Comments to the Copyright Office on Group Registration of Updates to a News Website
July 6, 2026
Alexandria, VA. June 29, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments supporting the U.S. Copyright Office's proposed expansion of eligibility for group registration of updates to news websites by removing restrictions that exclude subject-specific publications. -
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc. -
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry.
